about
Wnt5a regulates midbrain dopaminergic axon growth and guidanceSFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cellsWnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice.14-3-3ζ deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disordersA small synthetic cripto blocking Peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson's disease.Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter dysfunction.Characterization of the stability and bio-functionality of tethered proteins on bioengineered scaffolds: implications for stem cell biology and tissue repair.Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents.Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson modelFunctional characterization of Friedreich ataxia iPS-derived neuronal progenitors and their integration in the adult brain.Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens.Stem-cell-based strategies for the treatment of Parkinson's disease.A fully human inhibitory monoclonal antibody to the Wnt receptor RYKLiver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells.Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors.Genome-wide binding and mechanistic analyses of Smchd1-mediated epigenetic regulationNeurons derived from human embryonic stem cells extend long-distance axonal projections through growth along host white matter tracts after intra-cerebral transplantation.Dopamine Receptor Antagonists Enhance Proliferation and Neurogenesis of Midbrain Lmx1a-expressing ProgenitorsOver-Expression of Meteorin Drives Gliogenesis Following Striatal Injury.GAPTrap: A Simple Expression System for Pluripotent Stem Cells and Their Derivatives.Developing stem cell-based therapies for neural repairBiofunctionalisation of polymeric scaffolds for neural tissue engineering.Modulating Wnt signaling to improve cell replacement therapy for Parkinson's disease.Integrating Biomaterials and Stem Cells for Neural Regeneration.A PITX3-EGFP Reporter Line Reveals Connectivity of Dopamine and Non-dopamine Neuronal Subtypes in Grafts Generated from Human Embryonic Stem Cells.Long-Distance Axonal Growth and Protracted Functional Maturation of Neurons Derived from Human Induced Pluripotent Stem Cells After Intracerebral Transplantation.Functionalized composite scaffolds improve the engraftment of transplanted dopaminergic progenitors in a mouse model of Parkinson's disease.Chondroitinase improves midbrain pathway reconstruction by transplanted dopamine progenitors in Parkinsonian mice.Birth dating of midbrain dopamine neurons identifies A9 enriched tissue for transplantation into parkinsonian mice.Promoting engraftment of transplanted neural stem cells/progenitors using biofunctionalised electrospun scaffolds.Wnt/beta-catenin signaling blockade promotes neuronal induction and dopaminergic differentiation in embryonic stem cells.Organized development from human embryonic stem cells after injection into immunodeficient mice.Homophilic binding of the neural cell adhesion molecule CHL1 regulates development of ventral midbrain dopaminergic pathways.Chronic cocaine administration reduces striatal dopamine terminal density and striatal dopamine release which leads to drug-seeking behaviour.Cell intrinsic and extrinsic factors contribute to enhance neural circuit reconstruction following transplantation in Parkinsonian mice.Dopamine D2 receptor knockout mice develop features of Parkinson disease.Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size.Resolving pathobiological mechanisms relating to Huntington disease: gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells.Motor and behavioral phenotype in conditional mutants with targeted ablation of cortical D1 dopamine receptor-expressing cells.Huntingtin Inclusions Trigger Cellular Quiescence, Deactivate Apoptosis, and Lead to Delayed Necrosis.
P50
Q28568522-D3762092-8D68-4F6A-96CA-995F7AF88A3FQ28585649-BCCDC5D7-8C02-4E1C-B39C-F75A37194C26Q30480781-B79BE784-676E-4727-9BD7-BE25FEF103B5Q30658834-F0B1210E-53DE-43D4-B28A-8877FE266CD9Q33635593-2D7A5C0C-79D7-485D-9EF1-96021D0FF177Q33647525-1126210F-8E76-4AD8-B8A0-969883C6B14BQ33652222-8E758470-D65C-4FA6-93DE-2463E0FBFD2BQ33722351-2A339AF5-5A39-4CD7-8485-CFE08DE4E5ACQ33843358-0F42FFBA-3536-4811-AAAF-73076325BD81Q33856264-1F5C7198-50CB-4A1F-B33A-B57235AB2EBBQ34400951-29427936-F99D-4EF5-AD23-81762BCED8E4Q34649735-AB38B4A4-E884-4F02-A072-367A49DEE1E6Q34995094-CF1B839E-F735-48EE-9A47-D8CADFCA920CQ35005980-C3C01E93-7F22-4532-98ED-4934775DD0B3Q35484942-19F0A39E-EE32-41C5-AF9A-5A1BA0EE3F26Q35845991-C3A22D72-A93E-49FF-9D5B-007A6D2F74F3Q35848855-1F3B4862-13B4-4954-AD63-0F760E9918A4Q36953951-C795B4EC-0509-4A24-8DF8-46A5C6BF1B07Q37063142-7123AD0E-1B99-4114-A80A-8DC02CAE908EQ37274202-23F7BC36-1E0D-45AF-A3A1-BFCD808DE156Q37280895-E85E1E90-6A48-48F0-A502-511158E92442Q38001616-535787D6-1EC9-43E6-BC9C-0BBEF84AEA99Q38170947-759FACD2-5BE5-4BFE-9E00-9DFAAD31FB62Q38636212-A2D6DC9D-C4D9-43A1-8181-3CE54E8F91D8Q38693456-0C2D0329-8208-4C96-9059-6C80F1D8663AQ38716434-2CA154FA-B413-4E37-85F6-F411537E2A4EQ38829022-99CA1DCA-D273-48C7-B7EC-E37D9B7E0EEAQ38953975-CCA5AC51-9354-449D-909D-EEFC77F63AFBQ39248881-6D2A0AFE-B3A6-41E2-B63D-B88B6F948EF8Q39269390-6160221F-C66D-44DF-B740-BF877D342777Q39804668-DE41BA3E-E657-41EF-808D-0CF55957EBC6Q40519575-FAC30C08-86A1-406B-B18D-F3CBD4146852Q41516121-AB91A95B-D971-489F-83D7-298E88F4047CQ42480739-AB3B6E5E-0998-475A-A1E0-48C32B04E78EQ42513881-D50DED9E-D509-4574-BAD0-018F0FDC7CB9Q43256881-CC6AFCB4-E219-4B3A-B58D-401FAC3C5D46Q44173422-FD0D69EA-303F-46C4-8EA8-23AFD6013B29Q44777384-5D263C0A-FF92-47E2-979E-0FB2179DCBA3Q45304269-D0218440-3D35-4D02-B245-07F78CF9C961Q46372498-AF211241-9350-4BAA-A55D-5113D7BB8FF0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Clare L Parish
@ast
Clare L Parish
@en
Clare L Parish
@es
Clare L Parish
@nl
type
label
Clare L Parish
@ast
Clare L Parish
@en
Clare L Parish
@es
Clare L Parish
@nl
prefLabel
Clare L Parish
@ast
Clare L Parish
@en
Clare L Parish
@es
Clare L Parish
@nl
P106
P1153
8966004000
P21
P31
P496
0000-0001-8212-9884